April 2026- Thermo Fisher Scientific has announced that it has signed a definitive agreement to sell its microbiology business to Astorg for approximately $1.075 billion, including cash and a $50 million seller note.
The microbiology business offers antimicrobial susceptibility testing and culture media solutions for clinical, pharmaceutical, and food safety testing. It generated $645 million in revenue in 2025 and operates under Thermo Fisher’s Specialty Diagnostics segment.
Also rea: Izz Pharma Opens Advanced Pharmaceutical Factory in Nizwa to Strengthen Oman’s Health Security
“The transaction reflects our active management of the company and provides additional capital we can deploy to create shareholder value,” said Marc N. Casper, chairman and chief executive officer of Thermo Fisher. “We believe the microbiology business is an excellent fit within Astorg’s portfolio. We are confident in a smooth transition and wish the business and colleagues continued success after close under its new ownership.”
The company expects the transaction to close in the second half of 2026, subject to customary closing conditions and regulatory approvals. Thermo Fisher stated that the deal is expected to be dilutive to adjusted earnings per share by $0.15 in the first full year after closing and will share further details during its second quarter earnings call.
